Focused on the treatment of cancer patients with precise, controlled and highly active engineered T-cell therapies.
Autolus is a leader in cutting-edge T-cell therapies. Utilising advanced cell programming and manufacturing technologies, we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
We are a privately held biopharmaceutical company committed to bringing life-changing treatments to patients by reprogramming their own T-cells to more effectively combat cancer.
We are applying our extensive cell programming and manufacturing technology to develop a pipeline of precise, controlled and highly active engineered T-cell therapy products for the treatment of life-threatening cancers.